Overview
NBHL conducts proprietary drug discovery programs focused on respiratory diseases, chronic inflammation and central nervous system (CNS) disorders. We are open to discussing these internal programs with pharmaceutical partners on an ongoing basis and are seeking partners for clinical development and commercialization.
Internal pipelines are available for partnering opportunity
| Project | Indication | Drug type | Target molecule | Patent | Status |
|---|---|---|---|---|---|
| P001 | Cancer immunity Autoimmune disease |
mAb | EP4 | Issued | Optimization of mAb |
| P007 | Lung fibrosis Kidney fibrosis |
mAb | Chemokine GPCR | Issued | Prior to GLP test & CMC |
| P005 | Sleeping disorder Alzheimer’s disease |
small molecule | CK1σ | Issued | Optimization toward preclinical |
| P013 | Lung fibrosis Pain |
mAb | Lipid mediator GPCR | – | Discovery |
